Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

NCT07363720 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07363720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07363720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 29, 2026
Completion date
October 2, 2026
Enrollment
98 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy type 1 (nt1), narcolepsy with cataplexy